From CNBC: 2024-06-20 11:22:08

Gilead’s experimental HIV medicine, lenacapavir, was 100% effective in preventing HIV transmission in women in a late-stage trial, prompting optimism for new options in HIV prevention. The shot could be on the market by late 2025 pending FDA approval. Daily PrEP pills dominate the market, but longer-acting shots are gaining attention to combat HIV globally.



Read more at CNBC: Gilead PrEP lenacapavir succeeds in Phase 3 trial